The presentation of positive encore data at the 2023 ASCO Annual Meeting will likely boost investor confidence in Mirati Therapeutics and adagrasib's potential as a targeted treatment for KRASG12C-mutated advanced solid tumors. The recent inclusion of adagrasib in NCCN Guidelines for PDAC and CNS Cancers also supports the potential for regulatory approval in additional indications, which could positively impact the stock price in the short term.